Understanding vaccine hesitancy with PCV13 in children: Results of a survey in Shanghai, China
Open Access
- 27 April 2023
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (4) , e0284810
Abstract
A questionnaire survey for parents of children under 5 years of age was conducted to analyze vaccine hesitancy with the 13-valent pneumococcal conjugate vaccine (PCV13) in Shanghai, China. A total of 892 valid questionnaires were collected. Descriptive statistical methods, Chi-square test and effect size of Cohen were used. Among participants, 421 (48.8%) had children who had been vaccinated with PCV13 before the survey while 227 (26.73%) planned vaccination with PCV13 in the future. The main reasons for not receiving vaccination were the fear of adverse reactions (79, 26.7%), beyond vaccination age (69, 23.3%), and no need to vaccinate (44, 14.9%). Reducing vaccine hesitancy and increasing vaccination willingness can be achieved through health interventions, lower vaccine prices, and the adjustment of vaccination strategies.Keywords
This publication has 29 references indexed in Scilit:
- Vaccine hesitancy around the globe: Analysis of three years of WHO/UNICEF Joint Reporting Form data-2015–2017Vaccine, 2018
- Knowledge, attitudes, and behaviors of parents towards varicella and its vaccinationBMC Infectious Diseases, 2017
- Review of vaccine hesitancy: Rationale, remit and methodsVaccine, 2015
- Addressing vaccine hesitancy: The potential value of commercial and social marketing principles and practicesVaccine, 2015
- Diagnosing the determinants of vaccine hesitancy in specific subgroups: The Guide to Tailoring Immunization Programmes (TIP)Vaccine, 2015
- Vaccine hesitancy: Definition, scope and determinantsVaccine, 2015
- Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, AustraliaHuman Vaccines & Immunotherapeutics, 2015
- Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort studyThe Lancet Infectious Diseases, 2015
- A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderlyHuman Vaccines & Immunotherapeutics, 2015
- Cost of hospitalizing children with invasive pneumococcal pneumoniaVaccine, 2013